ArticleAnnals of nutrition & metabolism2026
Patient Acceptability of Partial Enteral Nutrition as a Concomitant Therapy to Adalimumab in Adults with Active Crohn's Disease: BIOPIC Trial.
Article in Annals of nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Partial enteral nutrition (PEN) is a dietary therapy for the management of Crohn's disease (CD). Although considered less restrictive than exclusive enteral nutrition, there are scarce data from patients with lived experience to support PEN. This study assessed dietary intake, the acceptability, and adherence to 50% PEN alongside treatment with adalimumab, for 6 weeks, in adults with active CD.
methodsAdherence to PEN was measured by three methods: an interview with a dietitian using an adherence questionnaire, dietary analysis from food diaries, and inventory from provided enteral nutrition formula and unused stock returned. Food diaries were also used to assess differences in intake between participants receiving 50% PEN (ADA + PEN group) and those who did not (ADA group).
resultsTwenty-nine of 41 patients (71%) took the PEN volume prescribed every day for 6 weeks; 39 (95%) met the full PEN volume prescribed for 5 weeks or more. Fifty-nine percent reported no issues adhering to PEN, 11.5% felt too full, 10.5% reported social life constraints, and 5% taste fatigue. Most respondents would use PEN again to manage CD (93%). Food-diary analysis also showed high level of adherence (median [IQR] daily energy intake provided by PEN: 53% [49; 71.2]). The median (IQR) percentage of enteral feed used from the volume provided was 96% (88; 101). Participants in the ADA + PEN group modified the unrestricted portion of their diet, particularly dinners.
conclusionThese results support the good acceptability rate of 50% PEN alongside treatment with adalimumab, emphasizing its potential of being a viable dietary treatment option for adults with CD. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.